1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1630
  5. Art Unit 1633
  6. Examiner Popa

Examiner Popa Ileana

1633-POPA-ILEANA

Employment Information

Art Unit:1633 — Drug, bio-affecting and body treating compositions
Group:1630 — Stem cells and cell culture and Nucleic Acid related therapy
Classes: 424 — Drug, bio-affecting and body treating compositions
435 — Chemistry: molecular biology and microbiology
514 — Drug, bio-affecting and body treating compositions
800 — Multicellular living organisms and unmodified parts thereof and related processes
536 — Organic compounds -- part of the class 532-570 series
604 — Surgery
506 — Combinatorial chemistry technology: method, library, apparatus
430 — Radiation imagery chemistry: process, composition, or product thereof
528 — Synthetic resins or natural rubbers -- part of the class 520 series
257 — Active solid-state devices (e.g., transistors, solid-state diodes)
Phone:(571) 272-5546
Email:ileana.popa@uspto.gov
Location:VA 22314
Title:Pat Examnr Biolgy
Service:21 years
Grade:GS-14

Grant Rate and Difficulty Ranking

93
3-Year Grant rate: 20% over 256 cases
Difficulty: Extremely Hard
Difficulty Percentile: 93rd

With Examiner Popa, you have a 20% chance of getting an issued patent by 3 years after the first office action. Examiner Popa is an extremely hard examiner and in the 93rd percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Popa, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1633

Examiner Popa's grant rate is lower than that of Art Unit 1633 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Popa 2.7
Art Unit 1633 2.0

Interview Benefit

Grant Rate without Interview

Examiner Popa has granted 38 of 190 cases without any applicant-requested interviews for a grant rate of 20%.

Grant Rate with Interview

Examiner Popa has granted 13 of 66 cases with at least one applicant-requested interview for a grant rate of 20%.

Interview Benefit

With Examiner Popa, conducting an interview does not change your chance of getting your patent granted.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
18049210 Cftr Mrna Compositions And Related Methods And Uses Rejection information available with a Premium Stats subscription. See our pricing. Patented View
17610942 Compositions And Methods For Targeting Multinucleated Cells Abandoned View
16331455 Gene Therapy For Patients With Fanconi Anemia Abandoned View
18000838 Nucleic Acid Molecule Targeting Mitf Gene And Use Thereof Abandoned View
17964523 Viral Vector Dosing Protocols Abandoned View
17970170 Immunostimulatory Compositions Abandoned View
17603220 Correction Of Beta-Thalassemia Phenotype By Genetically Engineered Hematopoietic Stem Cell Abandoned View
17686245 Use Of Inos Inhibitors To Increase Viral Yield In Culture Abandoned View
18112239 Methods For Analysis Of Somatic Mobile Elements, And Uses Thereof Abandoned View
16772759 Methods And Compositions For Treating Cancer Using Exosomes-Associated Gene Editing Abandoned View
15662190 Immolative Cell-Penetrating Complexes For Nucleic Acid Delivery Patented View
17051583 Enhanced Bcl11a Rnp / Crispr Delivery & Editing Using A 3xnls-Cas9 Patented View
18463155 Telomerase Reverse Transcriptase-Based Therapies Abandoned View
17759687 Mrnas Encoding Metabolic Reprogramming Polypeptides And Uses Thereof Abandoned View
16303903 Activity-Dependent Expression Constructs And Methods Of Using The Same Abandoned View
17939707 Immuno-Oncolytic Therapies Patented View
15468565 Oncolytic Tumor Viruses And Methods Of Use Patented View
17938008 Methods For Engineering Non-Neuronal Cells Into Neurons And Using Newly Engineered Neurons To Treat Neurodegenerative Diseases Abandoned View
17582289 Mutant Factor Viii Compositions And Methods Abandoned View
17396090 Formulations For Highly Purified Viral Particles Abandoned View
16947427 Novel Use Of Git Having Anti-Senescence Activity Abandoned View
17749012 Targeted Disruption Of The T Cell Receptor Abandoned View
17325292 Targeted Nanoparticles Abandoned View
17620331 Synthetic Genes For The Treatment Of Propionic Acidemia Caused By Mutations In Propionyl-Coa Carboxylase Alpha Abandoned View
16999459 Neural Stem Cell Delivery Of Therapeutic Agents Patented View
16302298 Polynucleotides Encoding Acyl-Coa Dehydrogenase, Very Long-Chain For The Treatment Of Very Long-Chain Acyl-Coa Dehydrogenase Deficiency Abandoned View
19029962 Ionizable Cationic Lipids Patented View
17438135 Optimised Rag1 Deficient Gene Therapy Patented View
17813304 Modulating Gamma-C-Cytokine Activity Abandoned View
17900233 Compositions And Methods For Delivering Messenger Rna Abandoned View
18306673 Tracking And Manipulating Cellular Rna Via Nuclear Delivery Of Crispr/cas9 Abandoned View
17339607 Transposition Of Nucleic Acids Into Eukaryotic Genomes With A Transposase From Heliothis Patented View
17859470 Delivery Of Gene Therapy Treatments Patented View
17294350 Relaxin Receptor 1 For Use In Treatment And Prevention Of Heart Failure Abandoned View
18752372 Method For Simply Constructing Two-Component Viral Vector And Related Applications Thereof Patented View
17938816 In Vivo Targeting Of Fibrosis By Anti-Cd5-Targeted Fap-Car T Mrna-Lnp Abandoned View
17099140 Compositions And Methods For The Treatment Of Cancer Using A Tet2 Engineered T Cell Therapy Abandoned View
17813984 Polynucleotides Encoding Porphobilinogen Deaminase For The Treatment Of Acute Intermittent Porphyria Patented View
17883973 Compositions And Methods For The Delivery Of Nucleic Acids Patented View
17705803 Messenger Rna Vaccines And Uses Thereof Patented View
16979138 Methods And Compositions For Use Of Tumor Self-Antigens In Adoptive Immunotherapy Patented View
17050918 Highly Knotted Molecular Topologies From Single-Stranded Nucleic Acids Patented View
17570962 Methods, Compositions, And Systems For Delivering Therapeutic And Diagnostic Agents Into Cells Abandoned View
18797392 Ionizable Cationic Lipids Patented View
17029436 Compounds And Compositions For Intracellular Delivery Of Therapeutic Agents Patented View
17426613 Treatment Of Aging Or Age-Related Disorders Using Xbp1 Abandoned View
16345299 Lipid Nanoparticle Mrna Vaccines Abandoned View
17553603 Rna-Nanostructured Double Robots And Methods Of Use Thereof Patented View
17083771 Process For The Preparation Of Erythrocytes Loaded With One Or More Substances Of Pharmaceutical Interest And So Obtained Erythrocytes Patented View
17845660 Anellovirus Compositions And Methods Of Use Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.